Plasma Fractionation Market continues to expand with Grifols S.A. acquiring GC Pharma’s plasma fractionation facility

Plasma fractionation refers to the medical practices of separating the antigens from the plasma of red blood cells, which in turn results in the formation of plasma. This separation results in higher concentrations of antigens than those found in whole blood. Plasma fractionation also leads to more efficient processing of drugs. Over the years, immunoglobulin has been used in the treatment of various diseases including lupus, myositis, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, and neurological diseases such as multiple sclerosis. As a matter of fact, regulatory agencies are granting approval immunoglobulin for some other diseases as well. Recently, in November 2020, Eli Lily and Company received the U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Hence, such factors can stimulate growth of the plasma fractionation market.

Request For Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/529

Another factor that could aid growth of the market in discussion is the rapidly increasing geriatric population. Compared to other demographics, elderly people are more susceptible to different types of diseases due to the weakened immune systems. As per the World Health Organization (WHO), by 2050, the global population aged 65 years and above is expected to reach around 2 billion increasing from 900 million in 2015. Thus, these factors can augment growth of the plasma fractionation market. Recently, in July 2020, Grifols S.A., a Spanish plasma-derived medicines company, acquired GC Pharma’s plasma fractionation facility in Montreal, Canada for US$ 460 million.

Plasma fractionated antibodies are also giving new hope to medical healthcare all over a wide spectrum of autoimmune, heredity-related diseases. Recent clinical trials have proved that plasma-derived antibodies can efficiently fight against diseases such as Parkinson's disease and rheumatoid arthritis. When it comes to regional impact, North America seems to be gaining significant traction in the plasma fractionation market. This is due to the early adoption of advanced technologies and growing healthcare expenditure across the region. On the contrary, Asia Pacific is exhibiting a positive outlook due to improve healthcare infrastructure across emerging economies such as India and China.

Several diseases that plasma protein therapeutics can treat include cardiovascular and endocrine disorders, autoimmune diseases, cancers, HIV/AIDS, inflammatory diseases, neurological disorders, and infections. There are several experimental treatments using antigens derived from plasma fractionated antibodies in clinical trials for several diseases. That being said, there are certain factors that can pose major challenges to the potential development of the market. For instance, plasma fractionation is expensive and has limited reimbursement options. Besides, the emergence of recombinant alternatives and stringent government regulations can impede growth of the plasma fractionation market in the near future.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/529

This report focuses on the top players in global market, like CSL Ltd., Octapharma AG, Grifols S.A, Baxalta Incorporated, Octapharma AG, and Kedrion S.p.A, Bio Products Laboratory, Sanquin, China Biologic Products, Inc., Biotest AG, and Laboratoire Français du Fractionnement et des Biotechnologies.

LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!

Buy Now with Discount for Premium Report (Flat US $ 2000 Off): https://www.coherentmarketinsights.com/promo/buynow/529

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.